Several GBM biomarkers have been previously identified, such as PTEN, EGFRvIII, IDH1, platelet‐derived growth factor receptor A, and tumor protein 53, and they have been used to define and classify GBM subtypes by using TCGA (McNamara et al., 2013). This evidence concerns the gene PTEN and glioblastoma.